G. Coteur

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

Robert Landewé, Jürgen Braun, Atul Deodhar et al. · Annals of the Rheumatic Diseases · 2013 · 468 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +11

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

Roy Fleischmann, Jiří Vencovský, Ronald van Vollenhoven et al. · Annals of the Rheumatic Diseases · 2008 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

William J. Sandborn, Stefan Schreiber, Brian G. Feagan et al. · Clinical Gastroenterology and Hepatology · 2011 · 170 citations

Medicine, Clinical Sciences, Pharmacotherapy +12

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

Kristian Reich, J.‐P. Ortonne, Alice B. Gottlieb et al. · British Journal of Dermatology · 2012 · 157 citations

Medicine, Pharmacology, Pharmacotherapy +13

Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease

G. Coteur, Brian G. Feagan, Dorothy L. Keininger et al. · Alimentary Pharmacology & Therapeutics · 2009 · 135 citations · Full text

Pharmacy, Internal Medicine, Functional Assessment +16